Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed
Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...
Decoding Biogen's Options Activity: What's the Big Picture?
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
BioPharma Dive1d
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Bioengineered Protein Drugs Market Size To Cross USD 672.7 Billion By 2034, Growing At A CAGR Of 6.2% - Report By Transparency Market Research, Inc.
The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...
Biogen announces initiation of dosing in TRANSCEND
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
4BIIB, LLY : Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed...
NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...
pharmaphorum7d
NICE agrees to look again at Alzheimer's drug Leqembi
The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...